Systemic Therapy AEs Yield Big Health Care Costs for Patients With Head & Neck Cancers

National Harbor, Md.—Adverse events (AEs) associated with systemic therapies prescribed for patients with advanced head and neck cancers may be responsible for a significant cost burden to the health care system, according to research presented at the Academy of Managed Care Pharmacy’s Nexus 2019 meeting.